RT Journal Article
SR Electronic
T1 COVID-19 Antibody Seroprevalence in Santa Clara County, California
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.14.20062463
DO 10.1101/2020.04.14.20062463
A1 Bendavid, Eran
A1 Mulaney, Bianca
A1 Sood, Neeraj
A1 Shah, Soleil
A1 Ling, Emilia
A1 Bromley-Dulfano, Rebecca
A1 Lai, Cara
A1 Weissberg, Zoe
A1 Saavedra-Walker, Rodrigo
A1 Tedrow, Jim
A1 Tversky, Dona
A1 Bogan, Andrew
A1 Kupiec, Thomas
A1 Eichner, Daniel
A1 Gupta, Ribhav
A1 Ioannidis, John P.A.
A1 Bhattacharya, Jay
YR 2020
UL http://medrxiv.org/content/early/2020/04/30/2020.04.14.20062463.abstract
AB Background Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in a community sample drawn from Santa Clara County.Methods On April 3-4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay. Participants were recruited using Facebook ads targeting a sample of individuals living within the county by demographic and geographic characteristics. We estimate weights to adjust our sample to match the zip code, sex, and race/ethnicity distribution within the county. We report both the weighted and unweighted prevalence of antibodies to SARS-CoV-2. We also adjust for test performance characteristics by combining data from 16 independent samples obtained from manufacturer’s data, regulatory submissions, and independent evaluations: 13 samples for specificity (3,324 specimens) and 3 samples for sensitivity (157 specimens).Results The raw prevalence of antibodies to SARS-CoV-2 in our sample was 1.5% (exact binomial 95CI 1.1-2.0%). Test performance specificity in our data was 99.5% (95CI 99.2-99.7%) and sensitivity was 82.8% (95CI 76.0-88.4%). The unweighted prevalence adjusted for test performance characteristics was 1.2% (95CI 0.7-1.8%). After weighting for population demographics of Santa Clara County, the prevalence was 2.8% (95CI 1.3-4.7%), using bootstrap to estimate confidence bounds. These prevalence point estimates imply that 54,000 (95CI 25,000 to 91,000 using weighted prevalence; 23,000 with 95CI 14,000-35,000 using unweighted prevalence) people were infected in Santa Clara County by early April, many more than the approximately 1,000 confirmed cases at the time of the survey.Conclusions The estimated population prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that the infection may be much more widespread than indicated by the number of confirmed cases. More studies are needed to improve precision of prevalence estimates. Locally-derived population prevalence estimates should be used to calibrate epidemic and mortality projections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge many individual donors who generously supported this project with gift awards. The funders had no role in the design and conduct of the study, nor in the decision to prepare and submit the manuscript for publication. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is not available for sharing at this time.